Findings that evolocumab significantly reduced the risk of major adverse CV events in adults at high CV risk without prior heart attack or stroke vs placebo. Topline data were announced from a phase 3 ...

An updated report on statistics regarding heart failure epidemiology and outcomes has been published by the HFSA.

The first clinical practice guidelines on assessment and management of diabetes distress among adults were presented at the annual meeting of the European Association for the Study of Diabetes.

Patients with cardio-renal-metabolic multimorbidity who maintain hematologic parameters within optimal ranges, vs those who do not, have decreased risk for mortality. Although their risk for all-cause ...

An investigational factor XI inhibitor shows early promise for treating atrial fibrillation in patients with a degree of kidney impairment.

The South Carolina Medical Affairs Committee conducted a Senate hearing on Wednesday, October 1, 2025, to deliberate S.323, a proposed bill prohibiting abortion in most circumstances, with few ...

Results of a systematic review showed that cognitive impairment and neuropsychiatric manifestations are common among patients with various forms of vasculitis.

Prevention strategies for cardiovascular manifestations of acute and long COVID are discussed in a report published online.

Oral semaglutide (25 mg) is effective for weight loss in adults with overweight or obesity without diabetes, according to a study.

Adverse cardiovascular outcomes and mortality risks were higher among patients with type 1 diabetes relative to type 2 diabetes.

For adults with obesity who do not have diabetes, the oral glucagon-like peptide-1 receptor agonist orforglipron yields significantly greater reductions in body weight than placebo.

Early prediction and prevention of venous thromboembolism is crucial in high-risk populations, such as hospitalized patients with bladder cancer.